<div id="readability-page-1"><div>RNS Number : 1901G Renalytix PLC 04 November 2025 Renalytix plc(&#34;Renalytix&#34; or the &#34;Company&#34;)Publication of Annual Report 2025&amp; Notice of 2025 Annual General MeetingLONDON and NEW YORK, 4 November 2025 - Renalytix plc (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that the Annual Report for the year ended 30 June 2025 and the Notice of 2025 Annual General Meeting (&#34;AGM&#34;) have now been published on the Company's website and will be posted to shareholders who have not consented to receive electronic communications tomorrow morning.The Annual report is available on the Company website here: https://investors.renalytix.com/annual-half-year-reports/The full Notice of AGM can be found here: https://investors.renalytix.com/documents/The AGM will be held in-person on 9 December 2025 at 10.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. Any shareholder wishing to attend is required to register by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0) 20 7933 8780.For further information, please contact:<div><table><tbody><tr><td>Renalytix plc</td><td colspan="2">www.renalytix.com</td></tr><tr><td>James McCullough, CEO</td><td colspan="2">Via Walbrook PR</td></tr><tr><td></td><td colspan="2"></td></tr><tr><td colspan="2">SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)</td><td>Tel: +44 (0) 20 3470 0470</td></tr><tr><td>Jeff Keating / David Hignell (Corporate Finance)Vadim Alexandre (Corporate Broking)</td><td colspan="2"></td></tr><tr><td></td><td colspan="2"></td></tr><tr><td>Oberon Capital (Joint Broker)</td><td colspan="2">Tel: +44 (0) 20 3179 5300</td></tr><tr><td>Mike Seabrook / Nick Lovering</td><td colspan="2"></td></tr><tr><td></td><td colspan="2"></td></tr><tr><td>Walbrook PR Limited</td><td colspan="2">Tel: 020 7933 8780 or renalytix@walbrookpr.com</td></tr><tr><td>Paul McManus / Alice Woodings</td><td colspan="2">Mob: 07980 541 893 / 07407 804 654</td></tr></tbody></table></div>About Renalytix (www.renalytix.com)Renalytix (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ACSUPGPUGUPAGRC</div></div>

RNLXY

RNLXD

Renalytix PLC has published its Annual Report for the year ended June 30, 2025, and the Notice of the 2025 Annual General Meeting (AGM). The AGM is scheduled for December 9, 2025, in London. Shareholders can access the Annual Report on the company's website and must register to attend the AGM. Renalytix is known for its FDA-approved kidney disease prognostic test, kidneyintelX.dkd, which is now commercially available in the U.S. and has received Medicare reimbursement.

REG - Renalytix PLC - Publication of Annual Report & Notice of AGM